Herbal Supplements and the Liver. Lauren Myers PA-C, MMsc

Similar documents
Spring 2017 Health & Wellness Seminar Series. Seminar 1: April 25 th, 2017

COMPLEMENTARY AND ALTERNATIVE THERAPIES IN LIVER DISEASES

Doc, is it good for my liver?

Expert Report (Sulfad)

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

EVALUATION OF ABNORMAL LIVER TESTS

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

Antioxidants & Detoxification

Marijuana and the Liver. Lauren Myers MMsc, PA-C

NON-ALCOHOLIC FATTY LIVER DISEASE:

This is your liver. Overview. Functions of the Liver 3/9/2015. This is your liver on Drugs. Drugs and the Liver Drug Induced Liver Injury (DILI)

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

LIV*Pro. Each vegetarian capsule contains:

U.S. FDA Perspective on Food Supplements/TM

Case Report Chinese Skullcap in Move Free Arthritis Supplement Causes Drug Induced Liver Injury and Pulmonary Infiltrates

Improving Access to Quality Medical Care Webinar Series

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

WHITE PAPER ACCESS TO GOOD QUALITY DIETARY SUPPLEMENTS

Management of the Patient with Chronic Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

Lucio C. Rovati, MD Chief Scientific Officer Executive Medical Director Rottapharm Madaus Monza Italy

FDA Introductory Remarks Stephanie O. Omokaro, MD

Pegasys Ribavirin

Silymarin effect on persistent allergic Rhinitis. Bakhshaee M, MD Rhinologist Assistant Prof. of MUMS

Case Report A Case of Supplement-Induced Hepatotoxicity

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

CAM and Hepatitis C: A Focus on Herbal Supplements

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

Non-Alcoholic Fatty Liver Disease

Intron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Drug Induced Liver Injury (DILI)

The Burden of Drug Induced Liver Injury

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Liver Pathology in the 0bese

Chapter 11. Major Characteristics of CAM. Research. CAM Healing Methods. Complementary and Alternative Medicine (CAM) CAM Healing Methods (continued)

The Skinny On Non Alcoholic Fatty Liver Disease

Intron A Hepatitis C. Intron A (interferon alfa-2b) Description

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

HCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD

Therapeutic Approaches to Cirrhotic versus Pre-Cirrhotic NASH

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

Therapies for DILI: NAC, Steroids or NRF-2 activators?

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

Intron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques

How Your Supplements Interact With Prescription Drugs

Liver Toxins (Hepatotoxins) Basics

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

20 Herbs that can fight cancer

Geneva Briggs, Pharm.D., BCPS MedOutcomes, Inc.

Disclosures Drug-induced Acute Liver Failure

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Natural health products: The Good, The Bad & Maybe Helpful. October 17, 2013 Dragana Skokovic-Sunjic, RPh, NCMP Clinical Pharmacist Hamilton FHT

Pharmacological management of viruses in obese patients

Liver Disease. By: Michael Martins

NONALCOHOLIC FATTY LIVER DISEASE

Worldwide Causes of HCC

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Autoimmune Hepatitis in Clinical Practice

Forward-looking Statements

Alcoholic hepatitis is a drug-induced disorder

Leonard B. Seeff, MD Hepatology Consultant, Retired

Appendix Table A Frequency of end-stage liver disease in inception cohort. Reference Exposure followup Frequency ESLD (%) Seeff-1 PTH 24 23/568 (4%) 7

Improving the Lives of Patients with Liver Diseases

Clinical Trials & Endpoints in NASH Cirrhosis

FACTS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

Pegasys Pegintron Ribavirin

Changing epidemiology of HCC in Italy

VIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms

NASH Regulatory Landscape. Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH

Gurus Garden 7201 Archibald Avn, Suite # 4-178, Alta Loma, CA United States of America

The Secret to More Energy, Boosted Metabolism, and Weight Loss with Herbs. Courtney Polivka

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

NAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology

Viral hepatitis and Hepatocellular Carcinoma

METABOLIC SYNDROME AND HCV: FROM HCV

Chronic Liver Disease after Acute Hepatocellular DILI

Ocaliva (obeticholic acid tablets)

Infergen Monotherapy. Infergen (interferon alfacon-1) Description

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement

DILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting

Drug Induced Liver Injury: A Clinical Perspective. Robert J. Fontana, MD

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Regulatory update from Europe:

Hepatitis C Management and Treatment

Diagnostic evaluation of suspected Drug-Induced Liver Injury

Hepatology For The Nonhepatologist

Featured Topic: Herbal Cleansing (5 slides)

An Update HBV Treatment

Transcription:

Herbal Supplements and the Liver Lauren Myers PA-C, MMsc

The Planner Lauren Myers, MMSc, PA-C - have no relevant financial relationships to disclose.

Herbal Dietary Supplements in the US 42% of Americans use some form of alternative therapy Approximately 19% use herbal dietary supplements (HDS) Reasons for use of HDS remedies Muscle building Weight loss Insomnia Well-being Cold prevention Menopausal symptoms Strader et al Am J Gastro 2002, Seeff et al. Hepatology 2008, Gardiner Arch Intern Med 2006, Nahin, RL etal National Health Statistics/NIH 2016

Herbal Dietary Supplements in the US 21% of adult prescription drug users also use HDS concurrently 69% do not disclose HDS use to their conventional provider Americans spent $12.8 billion out-of-pocket on natural product supplements 20-40% of liver patients use herbal supplements

Milk Thistle (Silymarin) Milk Thistle (Silybum marianum) most commonly used HDS in liver patients Herb native to Mediterranean region Used by ancient Greeks and Romans for liver and biliary complaints and to promote lactation Complex mixture of flavonolingans extracted from milk thistle seeds- known collectively as silymarin In vitro and animal studies demonstrating antioxidant, anti-inflammatory and anti-fibrotic properties Silymarin inhibits Hep C virus entry/fusion, RNA and protein synthesis Dosing 250-750mg capsules or tablets typically taken 2-3x daily Wagoner et al, Hepatology 2010, Wah-Kheong et al. Clin Gastro Hepatol 2017

Milk Thistle (Silymarin) and HCV HALT-C Trial Observational Data Trial designed to assess efficacy of long-term PEG-IFN those who failed prior standard treatment, advanced fibrosis Collected data on use of herbal supplements before/during trial Study data included serologic, biopsy and clinical outcomes (CTP score, death, cirrhosis complications) No difference in ALT or HCV levels in those who used silymarin vs. nonusers No association with clinical outcomes in crude or adjusted models Use was associated with fewer liver-related symptoms, improved quality of life than never users (adjusted for lifestyle factors and demographics) Seef et al, Hepatology 2008

Milk Thistle (Silymarin) and HCV Silymarin use in patients with untreated Hepatitis C Randomized, double-blind, placebo-controlled multicenter trial (N=154) 2 doses of silymarin (420mg or 700mg silymarin) vs placebo TID x 24 weeks Non-responders to PEG-IFN (note excluded cirrhotics, HIV co-infected) Outcomes measured: ALT levels/change, change in HCV RNA, quality of life (general and liver-related) and depression No change in ALT vs Placebo No changes in mental or physical health, liver related quality of life or depression No difference in adverse events between groups Fried, et al. JAMA 2012

Milk Thistle (Silymarin) and NASH Silymarin use in biopsy-proven NASH Randomized, double-blind, placebo-controlled trial with biopsy-proven NASH and a NAFLD activity score (NAS) 4 (NAS):sum of scores (0-3) on biopsy for steatosis, hepatocellular ballooning, lobular inflammation Silymarin 700mg vs placebo TID x 48 weeks in 99 patients Primary outcome was decrease 30% NAS score NAS changes similar between groups (33% silymarin and 26% placebo) Improvement in Fibrosis ( 1-point reduction) more frequently in silymarin vs placebo (22% vs 6%) No adverse events related to study drug Wah-Kheong et al. Clin Gastro Hepatol 2017

Milk Thistle (Silymarin) Milk thistle is very popular among patients with liver disease Side effects similar to placebo Silymarin lacks high quality evidence in improvement in clinical outcomes for HCV but may have a role yet in NASH

Turmeric (Curcumin) Turmeric (Curcuma longa) with yellow-colored active principle curcumin Perennial herb extensively used as spice, food preservative, coloring in India, China and South East Asia Used in traditional Indian medicine for treatment of biliary and hepatic disorders Curcumin is an antioxidant and has been shown to regulate pro-inflammatory and pro-fibrotic cytokines present in liver diseases Curcumin was shown to affect HCV viral envelope fluidity resulting in impairment of viral binding and fusion More studies needed FAO and WHO Expert Committee on Food additives report acceptable daily intake of curcumin up to 3mg/kg body weight Chattopadhyay et al. Cur Science 2004, Anggakusuma et al. Gut 2014, Nabavi et al Comprehensive Review in Food Science Food Safety 2014

The Dark Side of Herbal Dietary Supplements Regulatory framework established by Dietary Supplement Health and Education Act (DSHEA) of 1994 Manufacturer is responsible for safety, new dietary ingredients require pre-market review of safety data FDA approval is not required before marketing and can only take action if proven adulteration of HDS or injury due to HDS Incidence of clinically significant Drug Induced Liver Injury (DILI) is increasing along with the use of HDS in America (7%-20% within 10 year study period) DILI related to HDS is more likely to result in liver transplantation than injury related to conventional medications Navarro et al. Hepatology 2014

Herbal Dietary Supplements and DILI Drug Induced Liver Injury Network (DILIN) prospective study 33/300 patients took HDS either alone or in combination prescription drug DILI due to HDS associated with higher trends of bilirubin and longer duration Chalasani et al. Gastro 2008

Herbal Dietary Supplements associated with DILI Androstenedione Mistletoe Atractylis gummifera Pennyroyal Black cohosh Pyrrolizidine alkaloids Callilepis laureola Senna Chaparral Usnic acid Germander Valerian Greater celandine Herbalife (some products) Green tea extract Hydroxycut (some products) Kava Lipokinetix Licorice OxyELITE Pro

Herbal Dietary Supplements and DILI While HDS related cases of DILI are increasing, no reliable population-based statistics for incidence of toxicity Complicated by many HDS comprise mixtures of ingredients Vulnerable to variations in quality and strength Reports exist of contaminants of heavy metals, pharmaceuticals, microbial products and pesticides Analytical phytochemistry of HDS products implicated in DILI often reveal adulteration of the product, mislabeling or absence of botanical listed Mechanism of hepatotoxicity many cases is unknown but based on DILIN- most patients have a hepatocellular pattern of injury

https://livertox.nih.gov